LIVE

BEAM

Beam Therapeutics Inc.

BEAM

NASDAQ·Healthcare·Biotechnology·Mkt cap $3.4B

$34.79

▲ +3.91%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$15.60 - $36.88

P/E

-51.16

Fwd P/E

-7.45

Beta

2.20

Div Yield

0.00%

Avg Vol

2.2M

Shares Out

101.9M

Mkt Cap

$3.4B

Price action

Price chart

Up 68.4% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary Base Editing Technology
  • Broad Therapeutic Pipeline
  • Strategic Research Collaborations
  • Advanced Gene Modification Approach
▼

Bear Case

1 risk

  • High volatility (beta 2.2). Larger-than-normal price swings expected.

Growth

Revenue decline expected

Advancing Genetic Disease Treatments

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+35.8% over 3m

Quality

Loss-making

Strong fundamentals

Dividend

None

No dividend

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 4, 2026

“
Q2 26 RECAP

MAY 7, 2026

Reported EPS of -$0.91 vs -$1.03 consensus (+11.5% surprise). Revenue of $31.7M vs $11.0M expected (+189.1%). Beat on both top and bottom lines.

EPS beat +11.5%
Rev beat +189.1%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+11.5%

Next: May 4, 2026

Revenue trend · last 8Q

—

—

-90%

+1%

-28%

-32%

+280%

+325%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$11.8M

$14.3M

$30.1M

$7.5M

$8.5M

$9.7M

$114.1M

$31.7M

Margins · last 8Q

Gross

—

Operating

—

Profit

-297.2%

View full earnings history →

Wall Street consensus

4 analysts · 75% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

3

75%

Hold

1

25%

Sell

0%

Median Price Target

$59.50

▲ +71.0% vs $34.79

Low $39.00
Median $59.50
High $80.00

Latest: HC Wainwright · $80.00 · May 21, 2026

2 analysts covering

View full analyst page →

vs Industry

How BEAM stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.